That's funny, I must just have missed PenultiMAb...
Dec. 5 /PRNewswire/ -- Medarex, Inc., (Nasdaq: MEDX - news) showcased its expanded fully integrated human antibody technology platform at IBC's Antibody Engineering Conference. Medarex unveiled a unique crossbred mouse developed in partnership with the pharmaceutical division of Kirin Brewery Co., Ltd. as the newest addition to its UltiMAb(TM) Human Antibody Development System(SM).
With the UltiMAb platform, Medarex has assembled a unique family of genetically engineered mice for creating the entire spectrum of high-affinity, fully human antibodies. Medarex and Kirin combined their technologies, and the unique traits of the HuMAb-Mouse® and TC Mouse(TM), to create a new crossbred mouse that retains the capability to produce all human antibody isotypes with a robust immune response previously unseen in any human antibody producing mouse system. Medarex's HuMAb-Mouse has the proven ability to generate fully human antibodies with affinities in the picomolar range (as high as 1012). Developed by Kirin, the TC Mouse utilizes transchromosomic technology to generate human monoclonal antibodies of any isotype.
Conference presentations by Medarex and its technology partners, Biosite Discovery and Kirin, featured the three core technologies of Medarex's integrated human antibody platform: the UltiMAb Human Antibody Development System, T-12 Development(SM) and Trans-Phage Technology(SM). With these three technologies, Medarex believes it has created an unparalleled full-service antibody development system spanning target validation, novel therapeutic agent discovery, cGMP production, and regulatory expertise for rapid advancement to clinical testing.
``By combining our technology with the phage display technology developed by Biosite, and the transchromosome technology developed by Kirin, Medarex is offering our partners what we believe is the broadest range of human antibody discovery and development tools in the industry,'' said Donald L. Drakeman, President and CEO of Medarex. ``In addition, our experienced operations and regulatory teams have streamlined the process from target immunization through manufacturing and regulatory filing to create the T-12 Development program. With T-12, Medarex offers the potential for accelerated preclinical development, moving a novel antibody therapy from target to IND in about twelve months.''
``With our UltiMAb system, we have been able to directly produce high- affinity IgG1, IgG2, IgG3, IgG4, and IgA antibodies, all from a single fusion. The UltiMAb technology can generate the entire spectrum of human antibodies,'' said Nils Lonberg, Vice President and Scientific Director of Medarex's GenPharm subsidiary. ``We expect this will allow us to immediately access the widest possible variety of antibodies at the earliest stage of preclinical development.'' |
